These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 32975313)

  • 1. Using betaxolol for the prevention of paronychia induced by epidermal growth factor receptor inhibitors: a case-control cohort study.
    Lu CW; Wang TY; Yen CF; Chen KH; Wu CE; Wang CL; Hsu PC; Fang YF; Li SH; Ko HW; Tseng LC; Shih FY; Lin YJ; Chen MJ; Chen CB; Su Pang JH; Chung WH; Ko YS
    Int J Dermatol; 2021 Feb; 60(2):179-184. PubMed ID: 32975313
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of epidermal growth factor receptor inhibitor-induced severe paronychia with pyogenic granuloma-like lesions with topical betaxolol: an open-label observation study.
    Yen CF; Hsu CK; Yang HS; Lee CN; Chi CC; Chung WH; Wang CL; Pang JS; Wang CW; Ko YS; Lu CW
    Int J Dermatol; 2020 Mar; 59(3):326-332. PubMed ID: 31763692
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination of available topical beta-blockers and antibiotic ointment for epidermal growth factor receptor tyrosine kinase inhibitor-induced paronychia and pseudopyogenic granulomas in Taiwan.
    Liu HL; Chuang CH; Chen CL; Wei PJ; Yang CJ
    J Oncol Pharm Pract; 2023 Sep; 29(6):1374-1380. PubMed ID: 36112905
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationship between Paronychia and Drug Concentrations of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors.
    Masago K; Irie K; Fujita S; Imamichi F; Okada Y; Katakami N; Fukushima S; Yatabe Y
    Oncology; 2018; 95(4):251-256. PubMed ID: 29902802
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Papulopustules and paronychia in a lung carcinoma.
    Thakur V; Daroach M; Kumaran MS
    Eur J Intern Med; 2019 Apr; 62():e5-e6. PubMed ID: 30297249
    [No Abstract]   [Full Text] [Related]  

  • 6. EGFR-TKI rechallenge with bevacizumab in EGFR-mutant non-small cell lung cancer.
    Otsuka K; Hata A; Takeshita J; Okuda C; Kaji R; Masago K; Fujita S; Katakami N
    Cancer Chemother Pharmacol; 2015 Oct; 76(4):835-41. PubMed ID: 26349474
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Topical betaxolol for treating relapsing paronychia with pyogenic granuloma-like lesions induced by epidermal growth factor receptor inhibitors.
    Yen CF; Hsu CK; Lu CW
    J Am Acad Dermatol; 2018 Jun; 78(6):e143-e144. PubMed ID: 29339238
    [No Abstract]   [Full Text] [Related]  

  • 8. Clinical Factors Predicting Detection of T790M Mutation in Rebiopsy for EGFR-Mutant Non-small-cell Lung Cancer.
    Kawamura T; Kenmotsu H; Omori S; Nakashima K; Wakuda K; Ono A; Naito T; Murakami H; Omae K; Mori K; Tanigawara Y; Nakajima T; Ohde Y; Endo M; Takahashi T
    Clin Lung Cancer; 2018 Mar; 19(2):e247-e252. PubMed ID: 28866043
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Skin Toxicities Induced by Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors and their Influence on Treatment Adjustments in Lung Cancer Patients.
    Lee JS; Woo J; Kim TM; Kim N; Keam B; Jo SJ
    Acta Derm Venereol; 2024 Aug; 104():adv40555. PubMed ID: 39192813
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcome in advanced non-small cell lung cancer patients with successful rechallenge after recovery from epidermal growth factor receptor tyrosine kinase inhibitor-induced interstitial lung disease.
    Kashiwabara K; Semba H; Fujii S; Tsumura S
    Cancer Chemother Pharmacol; 2017 Apr; 79(4):705-710. PubMed ID: 28258422
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.
    Takeda M; Okamoto I; Tsurutani J; Oiso N; Kawada A; Nakagawa K
    Jpn J Clin Oncol; 2012 Jun; 42(6):528-33. PubMed ID: 22457323
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effects of switching EGFR-TKI treatments for non-small cell lung cancer because of adverse events.
    Sakata Y; Kawamura K; Shingu N; Hiroshige S; Yasuda Y; Eguchi Y; Anan K; Hisanaga J; Nitawaki T; Nakano A; Ichikado K
    Asia Pac J Clin Oncol; 2020 Apr; 16(2):e113-e117. PubMed ID: 30506897
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of clinical parameters and systemic inflammatory status on epidermal growth factor receptor-mutant non-small cell lung cancer patients readministration with epidermal growth factor receptor tyrosine kinase inhibitors.
    Chen YM; Lai CH; Rau KM; Huang CH; Chang HC; Chao TY; Tseng CC; Fang WF; Chung YH; Wang YH; Su MC; Huang KT; Liu SF; Chen HC; Chang YC; Chang YP; Wang CC; Lin MC
    BMC Cancer; 2016 Nov; 16(1):868. PubMed ID: 27821111
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Observational Study of Treatment Patterns in Patients with Epidermal Growth Factor Receptor (EGFR) Mutation-Positive Non-Small Cell Lung Cancer After First-Line EGFR-Tyrosine Kinase Inhibitors.
    Nadler E; Pavilack M; Espirito JL; Clark J; Fernandes A
    Adv Ther; 2020 Feb; 37(2):946-954. PubMed ID: 31955357
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development and Validation of a Machine Learning Model to Explore Tyrosine Kinase Inhibitor Response in Patients With Stage IV EGFR Variant-Positive Non-Small Cell Lung Cancer.
    Song J; Wang L; Ng NN; Zhao M; Shi J; Wu N; Li W; Liu Z; Yeom KW; Tian J
    JAMA Netw Open; 2020 Dec; 3(12):e2030442. PubMed ID: 33331920
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The association between clinical prognostic factors and epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) efficacy in advanced non-small-cell lung cancer patients: a retrospective assessment of 94 cases with EGFR mutations.
    Lin JH; Lin D; Xu L; Wang Q; Hu HH; Xu HP; He ZY
    Oncotarget; 2017 Jan; 8(2):3412-3421. PubMed ID: 27926500
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overview of current systemic management of EGFR-mutant NSCLC.
    Hsu WH; Yang JC; Mok TS; Loong HH
    Ann Oncol; 2018 Jan; 29(suppl_1):i3-i9. PubMed ID: 29462253
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incidence of hepatitis B reactivation during epidermal growth factor receptor tyrosine kinase inhibitor treatment in non-small-cell lung cancer patients.
    Yao ZH; Liao WY; Ho CC; Chen KY; Shih JY; Chen JS; Lin ZZ; Lin CC; Yang JC; Yu CJ
    Eur J Cancer; 2019 Aug; 117():107-115. PubMed ID: 31279301
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Crizotinib with or without an EGFR-TKI in treating EGFR-mutant NSCLC patients with acquired MET amplification after failure of EGFR-TKI therapy: a multicenter retrospective study.
    Wang W; Wang H; Lu P; Yu Z; Xu C; Zhuang W; Song Z
    J Transl Med; 2019 Feb; 17(1):52. PubMed ID: 30791921
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The epidermal growth factor receptor-tyrosine kinase inhibitor era has changed the causes of death of patients with advanced non-small-cell lung cancer.
    Wu WS; Chen YM; Tsai CM; Shih JF; Lee YC; Perng RP; Whang-Peng J
    J Chin Med Assoc; 2013 Dec; 76(12):682-5. PubMed ID: 24064329
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.